ES2079449T3 - 1-aril-1-hidroxi-1-sustituido-3-(4-sustituido-1-piperazinil)-2-propanonas y su utilizacion en el tratamiento de los trastornos neurogenicos de la vejiga. - Google Patents

1-aril-1-hidroxi-1-sustituido-3-(4-sustituido-1-piperazinil)-2-propanonas y su utilizacion en el tratamiento de los trastornos neurogenicos de la vejiga.

Info

Publication number
ES2079449T3
ES2079449T3 ES90312632T ES90312632T ES2079449T3 ES 2079449 T3 ES2079449 T3 ES 2079449T3 ES 90312632 T ES90312632 T ES 90312632T ES 90312632 T ES90312632 T ES 90312632T ES 2079449 T3 ES2079449 T3 ES 2079449T3
Authority
ES
Spain
Prior art keywords
substituted
phenyl
alkyl
carbons
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90312632T
Other languages
English (en)
Inventor
Daniel Wilbur Mcpherson
John Paul Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Marion Merrell Dow Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marion Merrell Dow Inc filed Critical Marion Merrell Dow Inc
Application granted granted Critical
Publication of ES2079449T3 publication Critical patent/ES2079449T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA (I): EN LA CUAL R SUB 1 ES UN ALQUIL C SUB 1-C SUB 12, SIENDO DICHO ALQUIL DE CADENA RECTA O RAMIFICADA, ESTANDO SATURADO O INSATURADO, MONOSUBSTITUIDO O INSUBSTITUIDO, ESTANDO DICHOS SUBSTITUYENTES SELECCIONADOS ENTRE PIPERIDINA, PIRROLIDINA, MORFOLINA, TIOMORFOLINA O CICLOALQUIL DE ENTRE 3 Y 7 ATOMOS DE CARBONO, UN CICLOALQUIL DE ENTRE 3 Y 9 ATOMOS DE CARBONO, UN ALQUILCICLOALQUIL INFERIOR DE ENTRE 4 Y 9 ATOMOS DE CARBONO, O UN POLICICLOALQUIL DE ENTRE 2 Y 3 ANILLOS CONTENIENDO ENTRE 7 Y 12 ATOMOS DE CARBONO; R SUB 2 ES HIDROGENO, FENIL, FENIL SUBSTITUIDO DE FORMA SIMPLE O MULTIPLE CON HALOGENO, HIDROXIDO, ALCOXIDO INFERIOR, DIOXIDO DE METILENO, NITRO, ALQUIL INFERIOR O TRIFLUOROMETIL, ALQUIL INFERIOR, SIENDO DICHO ALQUIL DE CADENA RECTA O RAMIFICADA, ESTANDO SATURADO, INSATURADO, O SIENDO CICLICO Y ESTANDO SUBSTITUIDO O INSUBSTITUIDO, ESTANDO SELECCIONADOS DICHOS SUBSTITUYENTES ENTRE TIENIL, PIRROLIL, PIRIDIL, FURANIL, HIDROXIDO, ALCOXIDO INFERIOR, OACETOXIALQUIL EN EL QUE EL GRUPO ALQUIL TIENE ENTRE 1 Y 3 ATOMOS DE CARBONO, FENIL, FENIL SUBSTITUIDO CON HALOGENO, HIDROXIDO, ALCOXIDO INFERIOR, ALQUIL INFERIOR, NITRO, DIOXIDO DE METILO O TRIFLUOROMETIL, PH ES FENIL O FENIL PARA-SUBSTITUIDO POR HALOGENO, ALQUIL INFERIOR, ALCOXIDO INFERIOR O TRIFLUOROMETIL. TAMBIEN SE PRESENTAN LAS SALES NO TOXICAS FARMACEUTICAMENTE ACEPTABLES DEL COMPUESTO. TAMBIEN SE DESCRIBE LA PREPARACION DE LOS COMPUESTOS, LAS COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD NEUROGENICA DE VEJIGA.
ES90312632T 1988-04-28 1990-11-20 1-aril-1-hidroxi-1-sustituido-3-(4-sustituido-1-piperazinil)-2-propanonas y su utilizacion en el tratamiento de los trastornos neurogenicos de la vejiga. Expired - Lifetime ES2079449T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18764988A 1988-04-28 1988-04-28
US07/372,009 US5001160A (en) 1988-04-28 1989-06-27 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
ZA909350A ZA909350B (en) 1988-04-28 1990-11-21 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
AU67005/90A AU634604B2 (en) 1988-04-28 1990-11-26 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1- piperazinyl-2-propanones and their use in treatment of neurogenic bladder disorders

Publications (1)

Publication Number Publication Date
ES2079449T3 true ES2079449T3 (es) 1996-01-16

Family

ID=40149700

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90312632T Expired - Lifetime ES2079449T3 (es) 1988-04-28 1990-11-20 1-aril-1-hidroxi-1-sustituido-3-(4-sustituido-1-piperazinil)-2-propanonas y su utilizacion en el tratamiento de los trastornos neurogenicos de la vejiga.

Country Status (9)

Country Link
US (1) US5001160A (es)
EP (1) EP0486734B1 (es)
JP (1) JPH0764833B2 (es)
AT (1) ATE127117T1 (es)
AU (1) AU634604B2 (es)
CA (1) CA2030397C (es)
DE (1) DE69022058T2 (es)
ES (1) ES2079449T3 (es)
ZA (1) ZA909350B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001160A (en) * 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
JP2004043433A (ja) * 2002-04-26 2004-02-12 Kitai Kagi Kofun Yugenkoshi モルフォリノケトン誘導体及びその用途
MXPA05000434A (es) 2002-07-08 2005-04-19 Ranbaxy Lab Ltd Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
WO2004064789A2 (en) * 2003-01-16 2004-08-05 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100436414C (zh) * 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
WO2006005980A1 (en) * 2004-06-16 2006-01-19 Ranbaxy Laboratories Limited Xanthine derivatives useful as muscarinic receptor antagonists
EP1781607A2 (en) * 2004-08-19 2007-05-09 Ranbaxy Laboratories Limited Pyrrolidine derivatives as muscarinic receptor antagonists
EP1794161A2 (en) * 2004-09-24 2007-06-13 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006035303A1 (en) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
EP1828126A1 (en) * 2004-12-15 2007-09-05 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
US20080319043A1 (en) * 2005-05-03 2008-12-25 Mohammad Salman 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125577A (en) * 1964-03-17 N-substttuted piperazinoalkyl
US2835676A (en) * 1953-07-14 1958-05-20 Merck & Co Inc Gamma-keto-tertiary amines and derivatives thereof
US3073842A (en) * 1957-07-22 1963-01-15 Endo Lab 1, 1 diphenyl-1-hydrocarbonoxy, 4-tertiary amino 2-butanones
US3157656A (en) * 1960-07-20 1964-11-17 Olin Mathieson Heterocyclic compounds
US3073854A (en) * 1960-11-28 1963-01-15 California Research Corp Trimethyllead methyl thioglycolate
US3395146A (en) * 1965-02-11 1968-07-30 Warner Lambert Pharmaceutical 4-substituted-2-benzhydryl-2-butanol derivatives
US3873546A (en) * 1974-02-06 1975-03-25 Abbott Lab Catalytic reduction of 4-methyl-{62 ,{62 -diphenyl-1-piperazine ethanol
NL8202636A (nl) * 1982-06-29 1984-01-16 Gist Brocades Nv Piperazinederivaten, werkwijzen ter bereiding daarvan en farmaceutische preparaten die deze verbindingen bevatten.
US5001160A (en) * 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders

Also Published As

Publication number Publication date
EP0486734B1 (en) 1995-08-30
EP0486734A1 (en) 1992-05-27
US5001160A (en) 1991-03-19
ATE127117T1 (de) 1995-09-15
JPH05125068A (ja) 1993-05-21
DE69022058D1 (de) 1995-10-05
AU634604B2 (en) 1993-02-25
CA2030397C (en) 1996-06-11
JPH0764833B2 (ja) 1995-07-12
ZA909350B (en) 1991-09-25
AU6700590A (en) 1992-06-11
DE69022058T2 (de) 1996-04-25
CA2030397A1 (en) 1992-05-21

Similar Documents

Publication Publication Date Title
ES2079449T3 (es) 1-aril-1-hidroxi-1-sustituido-3-(4-sustituido-1-piperazinil)-2-propanonas y su utilizacion en el tratamiento de los trastornos neurogenicos de la vejiga.
NZ240676A (en) Heterocyclic compounds substituted by a (piperidin-4-yl)-1-oxoalkyl group and pharmaceutical compositions thereof
DE3686248D1 (de) Piperidinderivat, seine verwendung und diese enthaltende pharmazeutische zusammensetzung.
DK0518558T3 (da) 1-methylcarbapenemderivater, deres fremstilling og deres anvendelse som antibiotika
PT81855B (pt) Processo de preparacao de arilciclobutilalquilaminas e de composicoes farmaceuticas que as contem
ZA902633B (en) New sulphonamides derived from benzo-cyclic or benzo heterocyclic acids,their preparation and their application in therapy
NO930783D0 (no) Kondenserte heterocykliske ketonderivater deres fremstilling og anveendelse
DE3877386D1 (de) Antikrebsverbindungen.
BG103426A (en) Derivatives of substituted 4-biphenyl-4-hydroxy-oil acids as inhibitors of matrix metalloproteases
ATE109770T1 (de) Derivate der coffeinsäure und pharmazeutische zusammensetzungen, die sie enthalten.
PT1216245E (pt) Derivados sulfonil-hidrazida farmaceuticamente activos
NO971861D0 (no) Nye syrer og estere av diosmetin og farmasöytiske sammensetninger inneholdende dem
ATE69605T1 (de) Azolylpropenyl- und azolylmethyloxiran-derivate und diese enthaltende fungizide.
EP1211253A4 (en) DIHYDROBENZOFURAN TRICYCLIC DERIVATIVES, THEIR PREPARATION METHOD AND AGENTS
FR2479219B1 (es)
DE68918832D1 (de) Benzoxazepinderivate.
DE3587653D1 (de) Sparsomycinderivate.
DE69011748T2 (de) Biphenyl-Derivate, Verfahren zu deren Herstellung und deren Zwischenprodukte.
ATE53570T1 (de) Aminoalkylnaphthalen-derivate mit pharmakologischer wirkung.
DE3689080D1 (de) Berbanderivate und ihre herstellung und pharmazeutische zubereitung.
NZ218030A (en) 3-imino-2,3-dihydropyridazine derivatives and pharmaceutical compositions
ES8102126A1 (es) Procedimiento para la produccion e una composicion sinergis-tica a base de derivados de naftiridina
GB2014561A (en) Amine derivatives, their preparation and pharmaceutical compositions containing them
SE8303410D0 (sv) Benzene derivatives, processes for their preparation and pharmaceutical compositions comprising them
FR2781155B1 (fr) Medicaments contenant des derives de polyhydroxyalkylpyrazine, les nouveaux derives de polyhydroxyalkylpyrazine et leur preparation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 486734

Country of ref document: ES